Morphine-6-O-sulfate (M6S) is as a mixed-action mu/delta (l/d) opioid receptor agonist with high potency and analgesic efficacy. These studies used assays of drug discrimination and schedule-controlled responding to assess abuse-liability, tolerance, and physical dependence as compared to morphine in rats. Attempts to train 0.3 mg/ kg (IP) M6S from saline failed, but all rats rapidly acquired the discrimination when the training dose was changed to 3.0 mg/kg morphine, and substitution tests showed that morphine and fentanyl both fully substituted for the training dose, M6S and M3A6S (3-O-acetyl ester of M6S) only partially substituted, and salvinorin A did not elicit morphine-like effects. Tolerance to response rate-decreasing effects was studied in rats administered either 1.0 or 3.0 mg/kg morphine or M6S before food-reinforced operant sessions. At both unit doses, tolerance to M6S-elicited rate suppression developed more slowly than tolerance to morphine-induced reductions in response rates. To assess dependence, rats were maintained on 1.0 mg/kg morphine or 1.0 mg/kg M6S until food-reinforced response rates were stable for at least 5 days. Rats were then administered saline or increasing doses of the opioid antagonist naltrexone (NTX) (0.3, 1.0, 3.0, or 10.0 mg/kg) in order to determine antagonist-precipitated withdrawal.
) is a prototypical l-opioid receptor agonist used for the treatment of chronic cancer pain and for short-term use in the treatment of strong acute pain states. 1 Although l-opioid receptor agonists such as fentanyl ( Figure 1D ) and morphine are effective analgesics, their clinical use is limited by undesirable effects including sedation, respiratory depression, constipation, physical dependence, and high abuse liability. 2 One strategy to improve the effectiveness and safety of l agonist analgesics is to combine them with adjuncts that target other receptors. Toward that end, much research has been focused on development of mixed action l/j opioids, which are reported to have lower abuse liability than many selective l receptor agonists. 3, 4 However, a common limitation among such compounds is their typically low efficacy at both l and j opioid receptors, 5, 6 usually resulting in low analgesic/antinociceptive efficacy in laboratory animals and in humans. [7] [8] [9] Considering this problem, the development of opioids with mixed agonist activity at l and d opioid receptors has attracted attention because multiple reports suggest that (as compared to l and d receptor-selective agonists) compounds activating both l and d receptors exhibit improved analgesic effects and safety profiles. [10] [11] [12] [13] We have recently demonstrated that an O-sulfate ester derivative of morphine, morphine-6-O-sulfate (M6S) ( Figure 1B ), acts as a mixed l/d agonist in rats, attenuating acute pain in normal rats and mechanical hyperalgesia in diabetic rats with analgesic effects 3-20-fold more potent and 2 to 4-fold higher in efficacy than those of morphine. 14, 15 In addition, these studies also demonstrated that tolerance to M6S-elicited analgesia develops more slowly than tolerance to morphine-induced analgesia in each of the pain modalities tested, and that no cross-tolerance exists between M6S and morphine 14, 15 However, the morphine-like abuse-related effects of M6S
and its capacity to induce physical dependence have not yet been characterized.
Therefore, the goal of the present studies was to compare abuse-related effects of M6S to those of morphine at doses within the analgesic range. We first determined the morphine-like discriminative stimulus effects of M6S. There is a strong correlation between discriminative stimulus effects of drugs in nonverbal species and subjective effects of those same drugs as reported by humans. [16] [17] [18] The discriminative stimulus properties of morphine and other l opioids have been extensively investigated in several different animal species, and it has been shown that, in agreement with studies in humans, opioids generalize with one another. [19] [20] [21] Thus, drug discrimination in laboratory rodents is a useful assay to determine the subjective effects of novel compounds in man. Then, the effects of chronic morphine or M6S on rates of food-maintained operant responding were examined in order to determine the rate of tolerance development to this behavioral effect at doses in the analgesic range. 14, 15 Finally, after complete tolerance to rate-decreasing effects had developed, we maintained animals on daily morphine or M6S and assessed the effects of the opioid antagonist naltrexone on response rates in order to gauge antagonist-precipitated withdrawal as a means of determining drug dependence. The use of schedule-controlled responding to study drug tolerance, dependence and withdrawal is well-established in behavioral pharmacology. Any drug that penetrates the central nervous system will disrupt operant responding at some dose, [22] [23] [24] and these disruptions are readily quantifiable as decreases in response rates when compared to control conditions. Combined with the results of previous reports 14, 15 knowledge gained from this study will help understand the pharmacology of mixed l/d opioids and foster better strategies in the design and development of novel opioids in order to engineer a safer and more effective therapeutic for chronic pain. Figure 1C ) were prepared in our laboratories utilizing the synthetic route published previously. 17 Structural confirmation for both M6S and M3A6S was accomplished using 1 H-and 13 C-NMR spectroscopy and high-resolution mass spectrometry. Fentanyl hydrochloride ( Figure 1D ) was obtained from the National Institute on Drug Abuse Drug Supply
Program (Bethesda, MD) and salvinorin A (free base, Figure 1E) was synthesized according to published methods 25 responding for the entire session was >90%; and (3) all available food pellets were earned during saline training sessions. These criteria were in effect for the duration of the study, such that all animals were required to pass 3 days of training prior to each substitution test. If a rat did not pass all three of the criteria previously stated, then the same training (saline or 0.3 mg/kg M6S) was repeated for the next training session. Because rats failed to acquire the discrimination of 0.3 mg/kg M6S from saline over a period of more than 2 months, animals were retrained to discriminate 3.0 mg/kg morphine from saline using the same methods as described above. This morphine discrimination was rapidly acquired by all animals (see Figure 2 ).
| Substitution testing
After stimulus control was established with the training drug morphine at a dose of 3.0 mg/kg, drug discrimination tests were con- 
| Schedule-controlled responding
Separate groups (n = 6 per group) of rats distinct from those used in drug discrimination studies were used in assays of food-maintained responding designed to assess tolerance to rate-decreasing effects of M6S and morphine and to test naltrexone-precipitated withdrawal in rats chronically maintained on M6S or morphine. All subjects were gradually shaped to a terminal FR10 schedule using food pellet (BioServ 45 mg dustless precision pellets) reinforcement as described above. All behavioral sessions lasted 60 minutes, or until 60 reinforcers were earned.
| Tolerance to rate-decreasing effects
Once responding was stable and reliable in two groups of rats (n = 6 per group), saline was injected SC 30 minutes before behavioral sessions, for 5 consecutive sessions. The average response rate for these five saline control sessions was set to 100% control for each individual animal in order to compensate for baseline differences in responding. In subsequent sessions, 1.0 mg/kg morphine or M6S was administered (SC) 30 minutes before behavioral sessions and these injections continued until response rates returned to 100% control levels for three consecutive sessions. Five more saline control sessions were interposed and used to recalculate 100% control response rates, and then the maintenance dose of both drugs was increased to 3.0 mg/kg.
Again, these injections continued until response rates returned to 100% control levels for three consecutive sessions. Both groups of rats received morphine or M6S 7 days per week, with no exceptions.
F I G U R E 2 Failure of rats to attain criterion discriminative performance with 0.3 mg/kg M6S over approximately two months (~30 M6S and~30 saline sessions), but rapid acquisition of 3.0 mg/ kg morphine as a discriminative stimulus in these same subjects.
Abscissa: percent of total responses emitted on the opioid lever. Ordinate: training sessions where saline, M6S or morphine was administered and discriminative performance was assessed
| Naltrexone-precipitated withdrawal
Three more groups (n = 6 per group) of rats were then shaped as previously described and maintained on saline, 1.0 mg/kg morphine or 1.0 mg/kg M6S until response rates were stable for at least 
| Data analysis
Graphical presentation of all drug discrimination and physical dependence data depict meanAESEM. Drug-discrimination data are expressed as percent drug-appropriate responding, which is the number of responses emitted on the drug-appropriate lever as a percentage of the total number of responses emitted. Subjects failing to emit 10 responses within 5 minutes of lever extension were deemed to be behaviorally disrupted and were not considered in the calculation of the percent drug-appropriate responding. Generalization was said to occur if ⩾80% of the responses were on the drug-appropriate lever, and the group mean was significantly different (via Kruskal-Wallis one-way analysis of variance (ANOVA) on ranks, followed by pairwise comparisons using the Dunn's method) from saline. Nonlinear regression analysis with a variable-slope sigmoidal dose-response curve was used to calculate the dose that elicited 50% morphine-appropriate responding (ED 50 ; with a set range of 0%-100%) for each individual animal using Graphpad Prism 4 (La Jolla, CA). These ED 50 values were averaged for each drug (n = 6 for all drugs) to determine mean ED 50 AE SEM. In the dependence and withdrawal studies, the data were expressed in terms of response rate (% control) compared to increasing doses of the opioid antagonist naltrexone to produce the dose response curve. Tolerance data were analyzed using a one-way ANOVA and a Dunnet's post hoc test to compare the first morphine or M6S injection to all subsequent injections. The dependence and withdrawal studies were then compared across naltrexone dose and treatment groups using a twoway ANOVA and a Bonferroni post hoc test.
3 | RESULTS
| Drug discrimination
Rats were initially injected with 0.3 mg/kg M6S or saline as training stimuli, however, all rats failed to achieve acceptable discriminative P < .0001), however, unlike M6S, this dose of M3A6S was not statistically different from the morphine training dose (P > .05. 
| Tolerance to rate-decreasing effects
Daily administration of saline had no systematic effects on response rates during the 5 day treatment period, and the mean rate for each animal during this time was set to 100% against which to gauge rate-decreasing effects of subsequent morphine or M6S injections and M6S-maintenance were not calculated because there were no significant differences in these two treatment groups.
| DISCUSSION
Morphine is metabolized to two major glucuronide conjugates: morphine-3-O-glucuronide (M3G) and morphine-6-O-glucuronide (M6G).
The major morphine metabolite (70%) in humans is M3G, which lacks any antinociceptive effects and is instead thought to antagonize the analgesic effects of morphine. 31 On the other hand, M6G
(about 10% of total metabolized morphine) is a more potent analgesic than morphine itself in both preclinical and clinical studies. 32 While Phase 3 clinical trials with M6G have been completed, it is not clear whether further clinical trials have been initiated, 33 and M6G is still awaiting FDA approval for use as an analgesic in humans. Indeed, controversy still surrounds the adverse effects profile of M6G, with debate continuing as to whether M6G is better or worse than morphine in this regard. 32 Nevertheless, the analgesic efficacy of M6G clearly demonstrates that structural modification at morphine's 6-hydroxyl position could lead to improvements in analgesic potency. This finding initially inspired us to investigate another 6-O-ester derivative of morphine, namely the 6-O-sulfate conjugate of morphine (M6S), in rat models of diabetic neuropathy. 14, 34 One common adverse effect limiting the chronic use of l opioid agonists is their notorious liability for abuse, physical dependence, and addiction. 35 Prescription l opioids are not only abused, but are also responsible for severe morbidity and death from overdose.
36,37
The present report provides an initial characterization of the morphine-like discriminative stimulus effects and physical dependence properties of the novel mixed-action l/d opioid M6S in rats. Here we demonstrate that, unlike morphine and fentanyl, M6S did not fully substitute for morphine in drug discrimination, although this is likely due to the limited dose range tested. Previous experiments in our lab determined adverse sedative effects at doses above 5.6 mg/ kg M6S, which would likely limit behavioral performance in the planned studies, 14, 28 thus, the maximum doses for morphine, M6S
and M3A6S were therefore limited to 5.6 mg/kg in all studies. Nevertheless, these in vivo data suggest that the interoceptive effects of morphine are only partially recapitulated by M6S at doses that produce maximal analgesic effects. 14 The trend of increasing morphinelike effects as the M6S dose is increased does suggest that M6S may elicit full morphine-like interoceptive effects at higher doses than those presently tested. However, the fact that M6S was approximately 3-fold more potent than morphine to elicit antinociceptive effects, 15, 38 but was here determined to be less potent than morphine in eliciting discriminative stimulus effects, perhaps suggests a widened therapeutic window as a function of the modification to the 6 position.
However, although M6S functioned as only a partial agonist in the drug discrimination assay across the dose range utilized, it is perhaps still reasonable to expect that M6S may possess reinforcing effects which could confer some abuse potential, although perhaps less than that observed with full l opioid agonists such as morphine and fentanyl. Similarly, we showed that the 3-O-acetyl ester prodrug of M6S (M3A6S) also acted as a partial agonist in the drug discrimination study, although the maximal percent drug-appropriate responding elicited by was not statistically different from that of morphine. M3A6S is a more lipophilic prodrug of M6S with a 400-fold better affinity for l-opioid receptors than for d-opioid receptors. 39 Therefore, M3A6S is a mu agonist with little to no delta opioid receptor affinity. Given the more lipophilic nature of M3A6S F I G U R E 5 Effects of saline or various doses of naltrexone on response rates in rats maintained on daily saline (white squares), 1.0 mg/kg morphine (gray circles) or 1.0 mg/kg M6S (white circles). Abscissa: as described in Figure 3 . Ordinate: dose of naltrexone in mg/kg on a logarithmic scale. "SAL" refers to saline control trials YADLAPALLI ET AL.
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relative to M6S, it is plausible to propose that the greater ability of M3A6S to cross the blood brain (BBB) barrier may be one factor that might explain its apparently more robust morphine-like discriminative profile compared to M6S. This might also highlight a more complicated process involving BBB penetration by the zwitterionic M6S molecule as a rate limiting step in lÀopioid receptor-mediated responses such as morphine-like discriminative stimulus effects.
Towards that end, we have demonstrated the intrinsic chemical stability of M6S across various biological buffers and matrices in vitro, 40 and these pharmacokinetic studies establish that M6S is also a stable molecule in vivo, with no measurable hydrolysis to morphine. Alternatively, the d-agonist properties of M6S may elicit effects which mask morphine-like subjective effects, a process known as perceptual masking, which is commonly observed in discrimination studies across various species and drugs. [41] [42] [43] [44] However, the l/d selectivity of M3A6S strongly favors affinity for l-opioid receptors, and it also substituted only partially, which seems to argue against the perceptual masking explanation for the incomplete substitution for morphine observed with M6S and M3A6S.
Previous studies on M6S and M3A6S 45 M3A6S in the present drug discrimination study are 3-fold higher than that of morphine and approximately 300 times higher than fentanyl, perhaps demonstrating the protective effects of l/d opioid agonism against morphine-like abuse-related effects. Furthermore, the fold difference between analgesic ED 50 and the ED 50 for morphine-like discriminative effects is higher for M6S (2-6 fold; 14, 15 ) compared to morphine, where the analgesic ED 50 for morphine is either similar to or higher than the ED 50 for morphine-like discriminative effects, indicating that the analgesic effects of M6S are observed at doses several fold less than those which are reported as morphine-like by rats trained to discriminate 3.0 mg/kg morphine from saline. This may suggest that analgesic effects of M6S could be obtained clinically at doses that do not elicit morphine-like subjective effects in humans.
Often included in preclinical assessments of abuse liability, 46 tolerance and dependence are two of several diagnostic criteria for opioid use disorder in humans. In our earlier studies, 14, 15 we demonstrated that M6S induces less analgesic tolerance and lacks cross-tolerance to morphine in both normal and diabetic rats, and our present drug discrimination study also provides evidence to suggest that M6S may have lower abuse liability than standard l opioid analgesics. Our current study also examined the capacity of M6S to induce tolerance to rate-decreasing effects on food-maintained responding, and to induce physical dependence, as assessed by naltrexone precipitated withdrawal effects on response rates. First, we observed that M6S-maintained rats (both 1 
